Sign In
Buy NVCR
$16.15
+0.330 (+2.09%)
At Close: Jun 03, 2026
3 Overlooked Stocks Set to Soar in 2026
08:45am, Tuesday, 05'th May 2026
These relatively small biotechs have recent catalysts that haven't yet been fully priced into their stocks.
International Markets and NovoCure (NVCR): A Deep Dive for Investors
10:16am, Monday, 04'th May 2026
Review NovoCure's (NVCR) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
NovoCure: Pancreatic Launch Looks Promising, But I'm Not A Believer Yet
12:35pm, Friday, 01'st May 2026
NovoCure Limited has resolved its CMS billing issue, with no material impact on operations or financials. Q1 2026 revenues grew 12% year-over-year to $174.1M; gross margins improved to 78%, and full-y
NovoCure Limited (NVCR) Q1 2026 Earnings Call Transcript
02:41pm, Thursday, 30'th Apr 2026
NovoCure Limited (NVCR) Q1 2026 Earnings Call Transcript
NovoCure (NVCR) Reports Q1 Loss, Beats Revenue Estimates
09:35am, Thursday, 30'th Apr 2026
NovoCure (NVCR) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.31 per share a year ago.
Novocure Reports First Quarter 2026 Financial Results
07:00am, Thursday, 30'th Apr 2026
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported financial results for the first quarter that ended March 31, 2026. Novocure is a global oncology company working to extend su
NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of “Hold” by Analysts
02:30am, Saturday, 25'th Apr 2026
Shares of NovoCure Limited (NASDAQ: NVCR - Get Free Report) have received an average rating of "Hold" from the seven ratings firms that are currently covering the company, MarketBeat Ratings reports.
Head to Head Contrast: NovoCure (NASDAQ:NVCR) versus Alterity Therapeutics (NASDAQ:ATHE)
01:11am, Thursday, 16'th Apr 2026
NovoCure (NASDAQ: NVCR - Get Free Report) and Alterity Therapeutics (NASDAQ: ATHE - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two
JPMorgan Chase & Co. Buys 144,024 Shares of NovoCure Limited $NVCR
04:56am, Saturday, 04'th Apr 2026
JPMorgan Chase and Co. lifted its stake in NovoCure Limited (NASDAQ: NVCR) by 104.2% in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned
Novocure to Report First Quarter 2026 Financial Results
07:00am, Wednesday, 01'st Apr 2026
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) will report financial results for the first quarter 2026 on April 30, 2026, before the U.S. financial markets open. Novocure management will
NovoCure Tumor Treating Fields Shows Improved Outcomes In Tough Pancreatic Cancer
11:19am, Thursday, 26'th Mar 2026
The stock is gaining traction as the company reported a disease control rate of 74.4%, significantly higher than the historical control of 48%.
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced positive results today from the Phase 2 PANOVA-4 trial of Tumor Treating Fields (TTFields) therapy concomitant with atezolizumab (
Novocure's Optune Lua Gets Japan Reimbursement for NSCLC Treatment
12:56pm, Monday, 09'th Mar 2026
NVCR gains Japan NHI reimbursement for Optune Lua in advanced NSCLC, expanding patient access and supporting adoption of its TTFields cancer therapy platform.
NovoCure (NVCR) Reliance on International Sales: What Investors Need to Know
10:16am, Monday, 02'nd Mar 2026
Explore NovoCure's (NVCR) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer
07:00am, Monday, 02'nd Mar 2026
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that Japan's Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua® through the country's National H
